We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups.
- Authors
Strauss, Gary M; Herndon, James E, 2nd; Maddaus, Michael A; Johnstone, David W; Johnson, Elizabeth A; Harpole, David H; Gillenwater, Heidi H; Watson, Dorothy M; Sugarbaker, David J; Schilsky, Richard L; Vokes, Everett E; Green, Mark R
- Abstract
Adjuvant chemotherapy for resected non-small-cell lung cancer (NSCLC) is now accepted on the basis of several randomized clinical trials (RCTs) that demonstrated improved survival. Although there is strong evidence that adjuvant chemotherapy is effective in stages II and IIIA NSCLC, its utility in stage IB disease is unclear. This report provides a mature analysis of Cancer and Leukemia Group B (CALGB) 9633, the only RCT designed specifically for stage IB NSCLC.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Vol 26, Issue 31, p5043
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2008.16.4855